TY - JOUR
T1 - Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)
AU - Blum, Ronald H.
AU - Corson, Joseph M.
AU - Wilson, Richard E.
AU - Greenberger, Joel S.
AU - Canellos, George P.
AU - Frei, Emil
PY - 1980/10/15
Y1 - 1980/10/15
N2 - Fifty consecutive adults with sarcoma were treated with Adriamycin (45 mg/m2) on day 1, cyclophosphamide (500 mg/m2) on day 2, and DTIC (400 mg/m2) on days 1 and 2 (CAD). Of the 23 patients with measurable metastatic disease, 4 patients (17%) had a complete response, 9 patients (39%) had a partial response, 5 patients (22%) had stabilization, but 5 patients (22%) did not respond. The actuarial survival of complete and partial responders was 31.5 months compared to 5.5 months for non‐responders (P < .005). Chemotherapy doses were escalated to a median lowest white count of 700 cells/mm3. Acute gastrointestinal toxicity and alopecia occurred in all patients. CAD differed from previously reported combinations by omission of vincristine, a two‐day dose schedule and dose rate intensification. CAD is recommended for patients with metastatic sarcoma.
AB - Fifty consecutive adults with sarcoma were treated with Adriamycin (45 mg/m2) on day 1, cyclophosphamide (500 mg/m2) on day 2, and DTIC (400 mg/m2) on days 1 and 2 (CAD). Of the 23 patients with measurable metastatic disease, 4 patients (17%) had a complete response, 9 patients (39%) had a partial response, 5 patients (22%) had stabilization, but 5 patients (22%) did not respond. The actuarial survival of complete and partial responders was 31.5 months compared to 5.5 months for non‐responders (P < .005). Chemotherapy doses were escalated to a median lowest white count of 700 cells/mm3. Acute gastrointestinal toxicity and alopecia occurred in all patients. CAD differed from previously reported combinations by omission of vincristine, a two‐day dose schedule and dose rate intensification. CAD is recommended for patients with metastatic sarcoma.
UR - http://www.scopus.com/inward/record.url?scp=0018926814&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M
DO - 10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M
M3 - Article
C2 - 7427876
AN - SCOPUS:0018926814
SN - 0008-543X
VL - 46
SP - 1722
EP - 1726
JO - Cancer
JF - Cancer
IS - 8
ER -